Patents Examined by Bao Q Li
  • Patent number: 10111946
    Abstract: The invention is drawn to compositions and methods for the induction of an immune response, in particular a strong CD8 T cell response, to a specific antigenic determinant without raising a significant antibody response to the antigenic determinant after a first, priming immunization. The method comprises administering to the host a recombinant poxviral vector comprising a transcriptional control element comprising an early and/or late element linked to a nucleotide sequence encoding the antigenic determinant. The recombinant poxviral vector comprises a transcriptional control element comprising an early and/or late element linked to a nucleotide sequence encoding the antigenic determinant. The late element may be stronger than the cowpox ATI promoter in HeLa cells.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: October 30, 2018
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Robin Steigerwald, Kay Brinkmann, Ulrike Dirmeier, Paul Chaplin
  • Patent number: 10112979
    Abstract: Influenza viruses have traditionally been administered by intramuscular injection. The invention is based on the idea of using alternative routes of delivery for influenza vaccines, more specifically routes that do not require as large a dose of antigen. Delivery of influenza antigen to the Langerhans cells is the route of choice according to the invention. This route has been found to be particularly useful for vaccinating patients who are naïve to influenza virus (i.e. have not previously mounted an immune response to an influenza virus), which means that it is advantageous for immunising young children.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: October 30, 2018
    Assignee: Seqirus UK Limited
    Inventor: Derek O'Hagan
  • Patent number: 10106819
    Abstract: The present invention relates to novel recombinant swinepox viruses and their use in vaccine compositions. The recombinant swinepox viruses of the invention are produced 5 by inserting one or more foreign genes into IL-18 binding protein (IL18bp) gene of swinepox virus. The invention is particularly suited to produce swine vaccines, particularly for vaccinating swine against PCV2 infection.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: October 23, 2018
    Assignee: Ceva Sante Animale
    Inventor: Takanori Sato
  • Patent number: 10105436
    Abstract: Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: October 23, 2018
    Assignee: Calidi Biotherapeutics, Inc.
    Inventors: Aladar Szalay, Boris Minev
  • Patent number: 10082512
    Abstract: Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting glycosylation, and more specifically fucosylation, on proteins in biological fluids, and comparing the detected glycosylation with reference values for the glycosylation of such proteins in healthy or disease states.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: September 25, 2018
    Assignee: Drexel University
    Inventors: Timothy M. Block, Anand Mehta, Mary Ann Comunale
  • Patent number: 10078076
    Abstract: Methods of evaluating the risk of infection after transplantation or immunosuppression in a subject are provided. Methods of determining whether a subject should be treated prophylactically with an anti-microbial agent are also provided herein. Kits for performing the methods described herein are also provided.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: September 18, 2018
    Assignee: Duke University
    Inventors: Scott M. Palmer, Kent J. Weinhold, Chi Wei Cliburn Chan, Laurie D. Snyder
  • Patent number: 10076569
    Abstract: Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: September 18, 2018
    Assignee: Calidi Biotherapeutics, Inc.
    Inventors: Aladar Szalay, Boris Minev
  • Patent number: 10064933
    Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: September 4, 2018
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
  • Patent number: 10059747
    Abstract: The present invention provides a viral vector or bacterial vector, said vector comprising a nucleic acid sequence encoding a Crimean-Congo Haemorrhagic Fever Virus (CCHFV) glycoprotein or antigenic fragment thereof; wherein said vector is capable of inducing an immune response in a subject. The present invention also provides compositions and uses of the vector in methods of medical treatment.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: August 28, 2018
    Assignee: THE SECRETARY OF STATE FOR HEALTH
    Inventors: Karen Buttigieg, Mile Carroll, Roger Hewson, Stuart Dowall, Stephen Findlay-Wilson, Aleksandra Miloszewska
  • Patent number: 10052377
    Abstract: The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: August 21, 2018
    Assignee: ADELAIDE RESEARCH & INNOVATION PTY LTD
    Inventor: Eric James Gowans
  • Patent number: 10039827
    Abstract: The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: August 7, 2018
    Assignee: Oncolytics Biotech Inc.
    Inventor: Matthew C. Coffey
  • Patent number: 10041050
    Abstract: The present invention relates to a method for endotoxin removal from a sample comprising the following steps: combining the sample comprising one or more target molecule(s) with a chromatography media comprising beads having an inner porous core functionalized with ligands capable of binding endotoxin and an outer porous layer without functional groups and a pore size small enough to exclude the target molecule from the inner core; and collecting the sample from the media, wherein the sample comprises an endotoxin level which is at least 75% less, preferably 90% less, than before the removal and the yield of the target molecule is at least 75%.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 7, 2018
    Assignee: GE Healthcare BioProcess R&D AB
    Inventors: Patrik Adielsson, Tobias E. Soderman, Anna Akerblom
  • Patent number: 10023844
    Abstract: The present invention aims at establishing a novel means for purifying norovirus VLPs. There is provided a purification method of norovirus virus-like particles, comprising: contacting solution containing norovirus virus-like particles with support for hydroxyapatite chromatography, binding the virus-like particles to the support, subsequently washing the support with buffer, and then eluting the virus-like particles from the support with buffer containing phosphate, wherein the phosphate concentration of the buffer used for elution is less than 10 mM.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: July 17, 2018
    Assignees: UMN PHARMA INC.
    Inventors: Masahiro Okada, Akiko Mukai, Tomonori Nishino, Daisuke Arinobu, Hiroyuki Ito, Mamoru Satoh
  • Patent number: 10010599
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 3, 2018
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
  • Patent number: 9982276
    Abstract: The present invention describes generation and the use of adenovirus variants (Ad) possessing modified capsid penton base protein where mutations in the penton based RGD loop are made to avoid Ad binding to cellular ?3-integrins. Specifically, the ablation of Ad penton base interaction with cellular ?3-integrins results in reduced activation of inflammation after intravenous Ad administration. Further, the introduction into penton RGD loop of non-RGD containing peptides, which mediate virus entry into the cell via new cellular receptors, allows for the efficient Ad-mediated gene delivery into target cells in vivo after intravascular virus administration and triggers significantly reduced toxicity associated with Ad injection.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: May 29, 2018
    Assignee: ADCURE BIOTECHNOLOGIES, LLC.
    Inventors: Dmitry M. Shayakhmetov, Nelson C. Di Paolo
  • Patent number: 9944903
    Abstract: Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including cancer, and as anti-tumor and/or antiangiogenic agents. The viruses also can be used in diagnostic methods.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: April 17, 2018
    Assignee: Genelux Corporation
    Inventors: Aladar A. Szalay, Alexa Frentzen, Yong A. Yu, Nanhai Chen, Qian Zhang
  • Patent number: 9944952
    Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: April 17, 2018
    Assignee: Universität Zürich
    Inventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
  • Patent number: 6680060
    Abstract: A live hepatitis A virus adapted to growth in MRC-5 cells, which HAV is preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation, methods for adapting HAV to growth in MRC-5, vaccine compositions and method of vaccinating humans against HAV infection.
    Type: Grant
    Filed: April 29, 2002
    Date of Patent: January 20, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ann W. Funkhouser, Suzanne U. Emerson, Robert H. Purcell, Eric D'Hondt